The filing confirms no unexpected regulatory hurdles beyond the two previously flagged divestitures, keeping the Q1 2027 close timeline intact. Monitor the November 30 EGM and final FTC/EU phase-1 clearances for any last-minute remedy expansion.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Oct 21 $34.98entry
- T+1 · 26d ago +0.20%α +1.38% · $35.05
- T+5 · 20d ago −1.31%α −0.87% · $34.52
- T+18 · todayOpen
- T+20 · tomorrow Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AkzoNobel provided an investor presentation confirming the Axalta merger remains on track to close in early 2027, with two-thirds of regulatory approvals secured and only two small divestitures required (AkzoNobel's European VR business and Axalta's North American Wood business, combined <€500M revenue). The $600M cost synergy target is reaffirmed as independent of remedies, and an EGM to appoint three Axanzo directors is set for November 30, 2026.
Key Financial Metrics
Key Facts
- Merger on track to close in early 2027, with two-thirds of regulatory approvals secured
- Remedies: divestiture of AkzoNobel's European VR business and Axalta's North American Wood business (<€500M combined revenue)
- $600M cost synergies reaffirmed, ~90% within 3 years of closing, plus 100-200bps revenue synergy uplift
- EGM to appoint three Axanzo directors scheduled for November 30, 2026
- Shareholders overwhelmingly approved the combination in August 2026 votes
Financial Impact
$600M cost synergies targeted; remedies involve <€500M revenue divestitures
Risk Factors
- Final regulatory signoffs in US and EU still pending despite phase-1 path
- Remedy divestiture processes (Axalta Wood US, Akzo Refinish Europe) could face buyer or valuation issues
- Integration execution risk post-close to achieve $600M cost synergy target
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0000950103-26-015959 |
| Document: 0000950103-26-015959-index-headers.html | 0000950103-26-015959 |
| Document: 0000950103-26-015959-index.html | 0000950103-26-015959 |
| Document: 0000950103-26-015959.txt | 0000950103-26-015959 |
Track record
44 reports on AXTA
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +16.39% at T+60 after the Jun 3, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry price pending
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $37.07 to $36.41 Now $36.56 −1.38% ▼ −1.78% −1.43% vs SPY
- Nov 6, 202610d ago 425 Neutral 5/10 Entry $37.53 to $37.38 Now $36.56 −2.58% ▼ −0.40% −0.03% vs SPY
- Nov 6, 202610d ago 425 Bullish 6/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Nov 6, 202610d ago Press Release Bullish 5/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Oct 29, 202618d ago 425 Bearish 4/10 Entry $34.07 to $35.84 Now $36.56 −7.31% ▼ −5.20% −5.67% vs SPY
- Oct 29, 202618d ago 425 Neutral 4/10 Entry $34.07 to $35.84 Now $36.56 +7.31% ▲ +5.20% +5.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers